FDA’s Response to HIV: A Perspective from the Commissioner
In a recent two-part FDA Voices series, Acting FDA Commissioner Ned Sharpless, MD, discusses how the agency’s medical product centers are engaged in important work spanning the entire spectrum of HIV research and product development, supporting both the domestic and global responses to HIV.
Dr. Sharpless also recounts his own formative experiences of working in an HIV lab at the National Institutes of Health and his subsequent medical residency and fellowship during the height of the AIDS epidemic.
His two articles provide an overview of how the agency is engaged in multiple aspects of the HIV response. This includes the development of effective treatments, approval of an expanding numbers of HIV drugs and drug combinations, vaccine research, development of more accurate diagnostic tests and reliable blood donor screening, and rigorous public education programs, as well advancing the availability of HIV therapies in underserved global markets through the President’s Emergency Plan for AIDS Relief (PEPFAR).
FDA’s Comprehensive Response to HIV—Part I
A multidisciplinary approach helps spur the development of effective treatments and approval of an expanding number of HIV drugs and drug combinations.
FDA’s Comprehensive Response to HIV—Part II
FDA plays a pivotal role in advancing HIV therapies in underserved global markets through the President’s Emergency Plan for AIDS Relief (PEPFAR).